A phase I/II clinical study is evaluating anti-tumor efficacy and safety of anti-LAG-3 monoclonal antibody, BMS-986016 alone, or in combination with anti-PD-1 antibody (NCT01968109). This evidence concerns the gene LAG3 and neoplasm.